Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies
09:46am, Wednesday, 29'th Nov 2023
The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.
3 Healthcare Stocks to Pick Up Before the Year-End Rally
03:39pm, Tuesday, 28'th Nov 2023
With their robustness and growth potential, healthcare stocks are becoming a focal point in portfolios worldwide. Moreover, the U.S. stands out at the forefront of healthcare spending, allocating a st
Novartis (NVS) Raises Mid-Term Sales Outlook; Outlines Strategy
02:17pm, Tuesday, 28'th Nov 2023
Novartis (NVS) increases its sales guidance for the mid-term (2022-2027) and outlines its growth strategy as a pure-play pharmaceutical company.
3 Large Drug Stocks That Have Outperformed Industry YTD
10:31am, Tuesday, 28'th Nov 2023
Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.
Novartis aims for 5% annual sales growth through 2027
01:26am, Tuesday, 28'th Nov 2023
Novartis said it was targeting annual sales growth of 5% per year until 2027 and a core operating income margin of about 40% by 2027, driven by innovative drugs on the market, after it severed ownersh
Legend Biotech highlights Novartis deal worth up to $1.11BN alongside 3Q results
07:18am, Monday, 20'th Nov 2023
Legend Biotech Corporation (NASDAQ:LEGN) highlighted an exclusive license agreement struck with Novartis AG (ADR) (NYSE:NVS) worth up to $1.11 billion as it released third-quarter results. Under the
2 overlooked stocks that crushed earnings but traded lower
06:22am, Monday, 20'th Nov 2023
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results. Regardless of sector or industry, every earnings sea
Novartis AG (NVS) 10th Annual ESG Investor Event Conference (Transcript)
03:24pm, Monday, 13'th Nov 2023
Novartis AG (NYSE:NVS ) 10th Annual ESG Investor Event Conference November 13, 2023 10:30 AM ET Company Participants Maria Victoria Cuevas - IR Vas Narasimhan - CEO Lutz Hegemann - President, Global H
Sandoz Group: Novartis Spinoff With A Double-Digit EBITDA CAGR Through 2028
10:40am, Saturday, 11'th Nov 2023
Sandoz is a global leader in the generics and biosimilars sector, with a strong position in the off-patent medicines market. The company recently listed and plans to aggressively pursue a slice of the
3 Spectacular High-Yield Dividend Stocks to Buy in November
10:00am, Sunday, 05'th Nov 2023
AbbVie should be poised to return to rapid growth and recently boosted its dividend. Novartis' spin-off of Sandoz doesn't diminish its attractiveness for income investors.
Novartis says drug candidate is successful in rare kidney disease trial
03:42am, Monday, 30'th Oct 2023
Novartis said its experimental drug atrasentan was shown to have a positive effect on kidney function in people suffering from a rare type of kidney disease in an interim analysis of a late-stage drug
New And Improved Novartis
11:51pm, Sunday, 29'th Oct 2023
Novartis recently completed the spin-off of Sandoz, which improved its growth and margin profile. The biopharma business is in good shape, with a decent collection of high-growth products and pipeline
3 No-Brainer Stocks to Buy for Under $100 Right Now
06:50am, Saturday, 28'th Oct 2023
AstraZeneca's slump presents a great buying opportunity. BioNTech's future prospects go well beyond COVID-19.
10 High-Yield Dividend Aristocrats Perfect For What's Coming Next
07:35am, Friday, 27'th Oct 2023
Investors are worried about soaring interest rates, a pending government shutdown, wars around the world, and a recession looming next year. History is very clear, market timing is the WORST thing you
2 Green Flags and 1 Red Flag for Novartis Stock
05:05am, Friday, 27'th Oct 2023
Novartis just spun off Sandoz, its generic division. The company has a huge pipeline of upcoming drug candidates.
